Comparison · NCT04163185-eadc2434
AXS-07 vs Placebo: Percentage of Subjects With Absence of Most Bothersome Symptom at Hour 2
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AXS-07 vs Placebo: Percentage of Subjects With Absence of Most Bothersome Symptom at Hour 2. Trial comparisons, record NCT04163185-eadc2434. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04163185-eadc2434
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.439 | 0.358 | 0.525 | wilson | |
| Risk in group 2 | 0.267 | 0.199 | 0.347 | wilson | |
| Risk difference, group 1 minus group 2 | 0.173 | 0.0581 | 0.281 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.65 | 1.17 | 2.31 | log | |
| Odds ratio, group 1 over group 2 | 2.16 | 1.29 | 3.6 | log | |
| Number needed to treat, for one more participant with the outcome on AXS-07 than on Placebo | 5.79 | 3.55 | 17.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AXS-07 | Taken once upon migraine~AXS-07 (MoSEIC meloxicam and rizatriptan): AXS-07 tablet taken once upon the earliest onset of migraine pain. | 58 | 132 | OG000 |
| Group 2 | Placebo | Taken once upon migraine~Placebo: Placebo tablet taken once upon the earliest onset of migraine pain. | 36 | 135 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percentage of Subjects With Absence of Most Bothersome Symptom at Hour 2
- Description
- Absence of Most Bothersome Symptom, defined at the onset of migraine at Hour 2
- Time frame
- Hour 2
- Population
- ITT Population
Source ClinicalTrials.gov
Trial
- Title
- Initiating Early Control of Migraine Pain and Associated Symptoms
- NCT number
- NCT04163185
- Phases
- PHASE3
- Conditions
- Migraine
- Interventions
- AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo
- Lead sponsor
- Axsome Therapeutics, Inc.
- Results first posted
- 2026-01-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04163185?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04163185-eadc2434